Siric > Research > Institutes > Institute for Functional Genomics (IGF)
logo-IGF-RVB-72di_petit

Address

Institute for Functional Genomics

141 Rue de la Cardonille

34094 Montpellier cedex 05

Director

Jean-Philippe PIN

Website

www.igf.cnrs.fr

The “Institut de Génomique Fonctionnelle” (IGF) / Institute for Functional Genomics is a major centre for basic research in Montpellier. IGF was evaluated as an “Institute that provides a very strong environment for research at the highest level”.

Research at IGF focuses on cell signaling and communication processes, as well as on disease mechanismsin the fields of neurobiology, cardiology, endocrinology and oncology. Major activities range from structural pharmacology to systems biology, from pre-clinical models of diseases to translational research.

One major goal at IGF is to identify novel concepts in molecular medicine offering new possibilities and strategies for diagnostic tools or therapies

  • Molecular Pharmacology
  • Physiology
  • Oncology
  • Endocrinology
  • Neurobiology

The IGF is strongly involved in technological innovation and six facilities are present in the institute with 4 of them qualified ISO 9001 (MGX, FPP, IPAM and Arpege):

  • The genomics facility MGX for applications of next generation sequencing.
  • The proteomics facility FPP: mass spectrometric analyses of small biological samples
  • The in vivo imaging facility IPAM, dedicated to the development of specific microscopic setups aimed at visualizing fluorescent cells or probes in anesthetized animals.
  • The Pharmacology-screening facility Arpege: development of innovative technologies to quantify signaling cascades based on medium throughput analysis of biological interactions.
  • The animal facility, dedicated to the generation, maintenance and functional exploration of mouse models of human diseases.
  • The vectorology facility PVM for the production of recombinant viral particles

Most of the IGF teams work in the context of a network of national and international collaborators. The IGF has strong interactions with biotech companies, included one (BioRéalités, 2007) that was created as a spin-off of an IGF team and a cooperative laboratory with Cisbio has been established in 2010. Since 2012, 9 patents were filled by IGF teams.